JNJ Stock Price Is Climbing — But Is Johnson & Johnson Really as Safe as Everyone Thinks?

There’s a particular kind of company that Wall Street takes for granted — the ones so old, so familiar, so embedded in everyday American life that analysts almost forget to question them. Johnson & Johnson is one of those companies. And right now, with JNJ stock quietly building momentum heading into an April earnings report, it’s worth stopping to actually look at what’s happening inside this 139-year-old institution.

The numbers are, in a word, serious. Fiscal 2025 closed with $94.2 billion in total revenue, up six percent year over year, and guidance for 2026 projects crossing the $100 billion threshold for the first time as a focused, pure-play healthcare business.

That projection matters more than it might seem. J&J isn’t hitting that number by selling baby powder or Band-Aids anymore. It spun off its consumer division as Kenvue back in 2023, and what remains is leaner, more expensive, and arguably more interesting — a company betting its next chapter on immunology drugs, robotic surgery systems, and billion-dollar biotech acquisitions.

Under CEO Joaquin Duato, the pivot has felt deliberate rather than reactive. There’s a sense that Duato inherited a company in the middle of an identity crisis and decided, fairly quickly, that the solution was subtraction. Remove the consumer noise. Focus on what actually generates margins.

The move hasn’t been without tension — longtime shareholders who associated J&J with its household brand legacy had to adjust their thinking — but the financial metrics suggest it’s working. Return on equity sits at 33.04%. Net margin at 28.46%. These aren’t defensive numbers. These are the numbers of a company playing offense.

The JNJ stock price story heading into April 2026 is partly about execution and partly about anticipation. The company has beaten earnings estimates in recent consecutive quarters — reporting $2.46 per share against a $2.43 estimate in the most recent quarter, and $2.80 versus $2.77 the quarter before. Small beats, yes. But consistent ones. Analysts tracking earnings surprise patterns know that consistency like this tends to compound.

The upcoming April 14 report carries a positive Earnings ESP of +3.91%, and historical data suggests stocks with that kind of setup beat estimates close to 70% of the time. Investors seem to believe something good is coming. It’s still unclear whether that confidence is fully priced in.

What’s harder to ignore is the pipeline news. In early 2026, J&J announced a $500 million R&D co-funding agreement with Royalty Pharma targeting a compound called JNJ-4804 — a first-in-class co-antibody designed to address chronic immune-mediated diseases by hitting both IL-23 and TNF pathways simultaneously. That’s not incremental science.

That’s the kind of mechanism that, if it works, rewrites treatment protocols. Recent FDA approval of ICOTYDE, backed by durability data from the ICONIC clinical program, also landed quietly but meaningfully for the immunology franchise. These aren’t press release wins. They’re the kind of regulatory steps that take years to build and months to fully appreciate.

The MedTech side is more complicated. J&J has been pursuing FDA clearance for the Ottava robotic surgery system, a product that would put it in direct competition with Intuitive Surgical’s entrenched da Vinci platform. If cleared, Ottava positions J&J in one of the fastest-growing surgical markets in the world.

Plans to spin off DePuy Synthes Orthopaedics by mid-2027 suggest further focus — trimming the slower-growth orthopedics business to concentrate resources on cardiovascular and soft-tissue interventions. Watching this strategy unfold, there’s a feeling that J&J is quietly building toward something, piece by piece, that the broader market hasn’t fully priced in yet.

It wouldn’t be honest to write about J&J right now without addressing the Impella recall situation. The FDA recently confirmed a Class I recall — the most serious category — involving purge cassettes sold with certain Johnson & Johnson MedTech Impella heart pumps.

More than 33,000 devices are affected. The concern is purge cassette leaks that could lead to pressure failures, pump stops, and in the most serious scenarios, loss of hemodynamic support. Four serious injuries have been linked to the issue. No deaths, as of this writing. But Class I is not a category the FDA assigns casually.

J&J acquired the Impella line through its $16.6 billion Abiomed purchase in 2022, and the device has now accumulated multiple recalls across 2025 and into 2026. That pattern raises legitimate questions about quality control integration — questions that don’t vanish simply because revenue is climbing.

It’s possible that the recall risk gets absorbed into J&J’s broader narrative the way most J&J controversies eventually do. The company has survived Tylenol tampering, talc litigation, hip implant failures, and mesh lawsuits. It holds one of only two AAA credit ratings among U.S. companies.

That rating isn’t ceremonial. It reflects a balance sheet capable of absorbing legal exposure while still funding $21 billion in projected free cash flow and aggressively acquiring biotech assets. History suggests J&J has a remarkable institutional capacity for crisis management — not always pretty, not always fast, but durable.

Outside the spreadsheets, something subtler is happening with JNJ stock. It’s attracting a particular kind of investor attention — the kind that tends to show up when a well-understood company is going through a genuine transformation. The Kenvue spinoff changed the story. The Ottava system could change it further. The immunology pipeline gives long-term holders something to believe in beyond the dividend, though that dividend — reliable, growing, historically dependable — remains its own argument for ownership.

North American investors navigating a volatile rate environment keep returning to names like J&J not out of excitement but out of something closer to trust built over decades.

Founded in 1886 when three brothers in New Jersey started packaging sterile surgical dressings, Johnson & Johnson has outlasted competitors, economic cycles, public health crises, and its own legal nightmares. That history doesn’t guarantee the future. But it does suggest the company knows how to survive — and occasionally, how to surprise.

The April 14 earnings call will tell part of the next chapter. What’s already visible suggests J&J is in a better strategic position than the stock’s relatively measured performance might indicate. It’s hard not to notice that the quiet ones sometimes move the furthest.